[Research progress of complement system activation involved in idiopathic pulmonary fibrosis]

Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease, and its pathogenesis remains unclear. In recent years, studies have shown that complement system activation plays an important role in the process of IPF. The inhibition of complement system activation provides a new approach for IPF treatment strategies. This article reviews the recent advances of complement system activation in the molecular mechanisms in the progress of IPF, and the potential therapeutic target in drug development, providing new perspectives for the prevention and treatment of IPF.